NeuroSense Therapeutics Warrant
NRSNW
6 hedge funds and large institutions have $36.4K invested in NeuroSense Therapeutics Warrant in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0.21% less ownership
Funds ownership: 2.23% → 2.02% (-0.21%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
38% less capital invested
Capital invested by funds: $59K → $36.4K (-$22.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$692 |
| 2 |
CS
Clear Street
New York
|
+$109 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.8K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$291 |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$179 |
NRSNW Hedge Fund Activity: Q3 2023 in Review
6 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q3 2023, worth a combined $36.4K — down 38% from $59K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $692. The largest seller was Citadel Advisors, cutting an estimated $4.8K.
- 6 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q3 2023, up from 5 in Q2 2023.
- Funds reported $36.4K of NeuroSense Therapeutics Warrant stock for Q3 2023, down 38% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics Warrant buyer in Q3 2023 was UBS Group, an estimated $692 added.
- The largest NeuroSense Therapeutics Warrant seller in Q3 2023 was Citadel Advisors, an estimated $4.8K sold.
Based on aggregated 13F filings for Q3 2023.